Literature DB >> 13726012

[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

H EHRINGER, O HORNYKIEWICZ.   

Abstract

Entities:  

Keywords:  BRAIN/chemistry; CATECHOLAMINES/metabolism; EXTRAPYRAMIDAL TRACTS/diseases

Mesh：

Substances：

Year:  1960        PMID： 13726012     DOI： 10.1007/bf01485901

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  18 in total

1.  Localization of dopamine-beta-oxidase in brain.

Authors:  S UDENFRIEND; C R CREVELING
Journal:  J Neurochem       Date:  1959-10       Impact factor: 5.372

2.  On the distribution in brain of monoamines and of enzymes responsible for their formation.

Authors:  A BERTLER; E ROSENGREN
Journal:  Experientia       Date:  1959-10-15

3.  Distribution of catechol compounds in human brain.

Authors:  I SANO; T GAMO; Y KAKIMOTO; K TANIGUCHI; M TAKESADA; K NISHINUMA
Journal:  Biochim Biophys Acta       Date:  1959-04

4.  The adrenal medulla and the biosynthesis of pressor amines.

Authors:  P HAGEN; A D WELCH
Journal:  Recent Prog Horm Res       Date:  1956

5.  Catechol compounds in rat tissues and in brains of different animals.

Authors:  K A MONTAGU
Journal:  Nature       Date:  1957-08-03       Impact factor: 49.962

6.  Intracellular distribution of catecholamines in the brain.

Authors:  H WEIL-MALHERBE; A D BONE
Journal:  Nature       Date:  1957-11-16       Impact factor: 49.962

7.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

8.  The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs.

Authors:  M VOGT
Journal:  J Physiol       Date:  1954-03-29       Impact factor: 5.182

9.  [Sympathomimetic activity of brain extracts].

Authors:  P HOLTZ
Journal:  Acta Physiol Scand       Date:  1950-05-30

10.  [On dopamine (hydroxytyramine) metabolism in the rat brain].

Authors:  G HOLZER; O HORNYKIEWICZ
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1959
View more
  289 in total

1.  Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease?

Authors:  Curt R Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

2.  Electrophysiological and morphological evidence for a GABAergic nigrostriatal pathway.

Authors:  M Rodríguez; T González-Hernández
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

3.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

4.  A REVIEW OF DRUG THERAPY IN PARKINSONISM.

Authors:  R C DUVOISIN
Journal:  Bull N Y Acad Med       Date:  1965-08

5.  [ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Arch Psychiatr Nervenkr       Date:  1964-12-02

6.  Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Authors:  Christian Pifl; Stephen J Kish; Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

7.  Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.

Authors:  Małgorzata Pokrzywa; Katarzyna Pawełek; Weronika Elżbieta Kucia; Szymon Sarbak; Erik Chorell; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Authors:  W Birkmayer; G Birkmayer; H Lechner; P Riederer
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

10.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.